Evidence map›Paper›PMID 40418646›Full record

ArticleOncoimmunology2025

Routing immunomodulatory cytokine-encoded mRNAs to the omentum: turning an enemy into an ally in peritoneal metastasis.

Leire Arrizabalaga, Ignacio Melero, Pedro Berraondo, Fernando Aranda

Abstract read
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Leire ArrizabalagaProgram of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.
Ignacio MeleroProgram of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID 0000-0002-1360-348X
Pedro BerraondoProgram of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID 0000-0001-7410-1865
Fernando ArandaProgram of Immunology and Immunotherapy, Cima Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Pamplona, Spain.ORCID 0000-0002-9364-474X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peritoneal metastases remain a significant clinical challenge owing to the immunosuppressive nature of the omentum, which serves as a protective niche for disseminated tumor cells. Our recent study explored the targeted delivery of immunomodulatory cytokine-encoded mRNAs to the omentum, aiming to shift its role from a tumor-supportive site to an immune-activating ally. Our findings highlight the potential of cytokine mRNA delivery as a novel and safe immunotherapeutic strategy for peritoneal metastases.

Indexed as

CytokinesOmentumPeritoneal NeoplasmsRNA, MessengerAnimalsHumansImmunomodulationImmunotherapyMiceCytokinesRNA, Messengerlocoregional immunotherapymRNAomentumperitoneal carcinomatosis

Identifiers

PMID40418646
PMCPMC12118438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.